Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,773 across all filing types
Latest filing 2023-03-16 Regulatory Filings
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
Regulatory Filings Classification · 1% confidence The document is a news release dated March 16, 2023, announcing scientific achievements and triggering performance-based payments of US$ 75M from Bristol Myers Squibb to Evotec related to a strategic partnership. It uses the EQS-News distribution service, which typically disseminates corporate news, press releases, or regulatory announcements. The content is an update on a business/scientific collaboration and associated financial milestones, not a formal periodic financial report (like 10-K or IR), a management discussion (MDA), or a specific shareholder vote result (DVA). Since it is a general corporate announcement about business progress and partnership milestones that doesn't fit neatly into the specific financial or governance categories, it best fits the general Regulatory Filings/News category, which serves as a fallback for miscellaneous corporate news releases distributed via official channels like EQS.
2023-03-16 English
Evotec receives 150 m loan from European Investment Bank
Capital/Financing Update Classification · 1% confidence The document is a news release dated February 10, 2023, announcing that Evotec SE has received a €150 million unsecured loan facility from the European Investment Bank (EIB). This financing is explicitly for R&D activities, equity investments, and the construction of a manufacturing facility. This content directly relates to the company's fundraising and capital structure changes. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a management discussion (MDA), but a specific announcement about securing debt financing.
2023-02-10 English
Evotec and Related Sciences expand integrated drug discovery and development partnership
Regulatory Filings Classification · 1% confidence The document is a press release format, identified by the 'EQS-News' header, date/time stamps, and the structure typical of corporate news dissemination. The content announces an expansion of a drug discovery partnership between Evotec SE and Related Sciences, detailing strategic collaboration terms, portfolio growth, and future capabilities (covalent inhibitors). This type of announcement, which details business developments, strategic agreements, and operational updates rather than formal financial statements (like 10-K or IR) or voting results, most closely aligns with a general corporate announcement. Since it is not a specific financial report, management discussion, or director dealing, and it is not merely announcing the publication of another report (RPA), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for material non-financial news releases distributed via regulatory channels.
2023-02-09 English
Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
Board/Management Information Classification · 1% confidence The document is a news release dated February 7, 2023, announcing a change in senior management: Laetitia Rouxel is succeeding Enno Spillner as Chief Financial Officer (CFO) of Evotec SE, effective April 1, 2023. This content directly relates to changes in the company's senior management team. This aligns perfectly with the definition for Board/Management Information (MANG). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific executive appointment.
2023-02-07 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement (1697 characters) published via EQS News, titled 'Evotec SE: Release according to Article 41 of the WpHG' and specifically concerns the 'Publication of total number of voting rights' following a 'Conditional capital increase'. This type of regulatory notification regarding the total number of shares/voting rights, especially when related to capital structure changes or shareholder rights, fits best under the category dealing with capital structure or general regulatory updates. Since it is a direct announcement of a change in voting rights and capital structure, it aligns closely with 'Capital/Financing Update' (CAP) or potentially a specific regulatory filing. However, the core subject is the total voting rights resulting from a capital measure. Given the options, 'Capital/Financing Update' (CAP) is the most specific fit for reporting changes in the total number of shares/voting rights resulting from a capital increase. It is not a full report (10-K, IR), nor is it a dividend notice (DIV) or director dealing (DIRS). It is a direct regulatory disclosure about capital structure.
2023-01-31 English
Evotec announces agreement with Janssen to develop immune-based therapies
Regulatory Filings Classification · 1% confidence The document is a news release dated January 26, 2023, announcing a strategic collaboration and license agreement between Evotec SE and Janssen Biotech regarding the development of immune-based therapies. It details financial terms (upfront payment, milestones, royalties) and strategic rationale. This type of announcement, which details a significant business development, partnership, or material event that is not a standard periodic financial report (like 10-K or IR), typically falls under general regulatory news or corporate updates. Since it is not a specific filing like a Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), and it is a formal announcement disseminated via EQS News, it best fits the 'Regulatory Filings' (RNS) category as a general corporate news item, or potentially a 'Miscellaneous' category if one existed, but RNS serves as the best fit for non-standard, material corporate news releases.
2023-01-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.